VivoSim Labs, INC. (NASDAQ:VIVS)
| Market Cap | $4.33M-88.4% |
| Revenue (ttm) | $135.00K-3.6% |
| Net Income | -$10.27M-417.8% |
| EPS | -$0.62-235.6% |
| Shares Out | 16.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,188,469 |
| Open | $0.28 |
| Previous Close | $0.29 |
| Day's Range | $0.25 - $0.38 |
| 52-Week Range | $0.12 - $3.40 |
| Beta | 1.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 9, 2027 |
About VIVS
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
VivoSim Labs, INC. Stock Analysis — InsiderScore
VivoSim Labs, INC. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 105th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at VivoSim Labs, INC. bought $2.8K of stock across 1 purchase in the last 90 days, the largest of them $2.8K.
None of these purchases could be measured against an existing holding, so this part of the factor scores on dollars alone.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Feb 9, 2027Earnings report
$VIVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VIVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VIVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VIVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
VIVS Revenue by Segment
| Non-cash stock-based compensation | $235.00K | 80.76% |
| Cost of services provided | $56.00K | 19.24% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New VIVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VIVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VIVS
| VXFVanguard Extended Market ETF | $2.38K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VIVS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Multiple major contract wins with pharmaceutical companies and upward revenue guidance revisions signal strong business momentum and positive momentum.
Recent Insider Activity
Insider Score Trend Over Time
+10.0 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
